Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05725291 · ClinicalTrials.gov registry record · Phase 1
AMT-116 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Multitude Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 10
- Study locations
NCT05725291: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Multitude Therapeutics.
NCT05725291 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Multitude Therapeutics. The registered enrollment target is 80 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05725291, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Multitude Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 10
- Study locations
Study Summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
Primary Outcome
The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data
Conditions Studied
Interventions
- DRUG AMT-116
Study Locations (10)
Victoria
- Alfred Hospital - Victoria Park
- Austin Health - Victoria Park
- Cabrini Hospital - Victoria Park
Colorado
- Sarah Cannon Research Institute - Denver
Texas
- Mary Crowley Cancer Research Centers - Dallas
California
- University of California San Francisco Cancer Center - San Francisco
North Carolina
- Carolina BioOncology Institute, LLC - Cary
New South Wales
- Macquarie University Hospital - Sydney
Queensland
- ICON Cancer Centre - Brisbane
South Australia
- Southern Oncology Clinical Research Unit - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What NCT05725291 shows while recruiting
NCT05725291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which AMT-116 is the first listed.
NCT05725291 lists 10 locations in 8 states (Victoria, Colorado, Texas).
Frequently Asked Questions
What is clinical trial NCT05725291 about?
NCT05725291 is a clinical study titled "AMT-116 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
What is the current status of trial NCT05725291?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-07-25. Estimated completion is 2026-12-30.
What conditions does trial NCT05725291 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05725291?
The interventions under investigation include: AMT-116 (DRUG).
Who is sponsoring clinical trial NCT05725291?
This trial is sponsored by Multitude Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05725291 being conducted?
This trial has 10 study locations across Colorado, Texas, California, North Carolina, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05725291's enrollment target sits among peer trials
80 134th of 189 higher than 54 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI